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Parkinson’s disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor
symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD
(dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional
stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7
women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were
performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued.
Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status.
DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off,
while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN
activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications
may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity
during external stimulation among ndPD patients.

1. Introduction
Parkinson’s disease (PD) is characterized by tremor, muscular
rigidity, and bradykinesia. Individuals with PD also experience nonmotor symptoms, such as impairments in cognitive
and emotional processing, including depression, anxiety, and
apathy (see Blonder and Slevin [1] for a review). Although
dopaminergic drugs show considerable efficacy in treating
PD motor symptoms, dopaminergic pharmacotherapy may
have variable effects on cognitive and affective processing

depending upon the mood state of the PD patient. In
particular, Blonder et al. [2] found that depressed PD (dPD)
patients performed more poorly on neuropsychological tests
of working memory and facial affect recognition while on
dopaminergic medications than while off. Nondepressed PD
(ndPD) patients showed the opposite pattern.
Functional neuroimaging studies of dPD patients have
shown abnormalities in the caudate, orbitofrontal cortex,
medial frontal cortex, anterior cingulate, limbic system,
and thalamus [3–7]. Few studies have examined regional
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brain response to dopaminergic drugs during cognitive or
affective processing in dPD, although functional imaging
studies suggest that dopaminergic drugs modulate cognitive
function among PD patients generally. (Please note that
the wording “activity” is used broadly in referring to an
implied underlying neural activity. Absolute levels of brain
activity such as those quantified by cerebral blood flow and/or
metabolism cannot be measured in fMRI experiments using
BOLD contrast; only changes in activity can be detected.
Positive changes in the activity level induced by a task
relative to baseline are called “activation.” Negative changes
in the activity level induced by a task relative to baseline are
called “deactivation.” The wording “fMRI response” refers
to observations of either activation or deactivation.) For
example, Mattay et al. [8] found that activation in the
dorsolateral prefrontal cortex, anterior cingulate, and parietal
cortex during a working memory task was more focused
while PD patients were on dopaminergic medications and
more diffuse while they were off medication. While there
were no statistically significant differences in cognitive test
performance as a function of medication status, motor
performance positively correlated with activation in cortical
motor regions during the dopamine-replete state. Participant
mood was not reported. Argyelan et al. [9], using a motor
sequence learning task, showed that normal deactivation in
the ventromedial prefrontal cortex (VMPFC) was suppressed
in ndPD patients when they were on dopaminergic medication. Also, treatment-mediated changes in the deactivation
response correlated with baseline task performance. Cools et
al. [10] used PET to study PD patients on and off levodopa
and found no significant differences in performance during
planning and spatial working memory tasks as a function
of medication status. L-Dopa decreased cerebral blood flow
in the right dorsolateral prefrontal cortex during both the
spatial working memory and planning tasks relative to
the visuomotor control task. During the working memory
task, the levodopa-induced decrease was accompanied by a
significant relative increase in right occipital lobe blood flow.
The authors excluded patients with a history of depression
unrelated to PD, but participant mood in association with
PD is not reported. Tessitore et al. [11] used fMRI to study
dopaminergic modulation of affective processing in PD.
They found a lack of amygdala activation in response to
angry and fearful facial expressions in patients deprived of
dopaminergic medications. In contrast, normal volunteers
showed robust responses. Amygdala activation in PD was
partially restored when dopaminergic pharmacotherapy was
reinstituted. In spite of the increase in amygdala activation
during the dopamine-replete state, performance on the emotional face recognition task did not differ as a function of
medication status. Five of nine patients in that study had a
history of depression, but the investigators did not find an
association between depression and amygdala response. This
may have been due to low statistical power related to small
sample size.
The goal of the current study was to examine the effects of
dopaminergic medication on regional brain fMRI responses
to affective stimuli in depressed versus nondepressed PD
patients. As described above, Blonder et al. [2] found that
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dPD patients showed increased depression severity based
on Geriatric Depression Scale [12] scores and performed
more poorly on verbal memory and facial affect recognition
while on dopaminergic drugs than while off. Dopaminergic
medications had the opposite effect on memory and affect
recognition in ndPD patients in that performance improved
on dopaminergic drugs. Past neuropsychological studies have
shown impairments in affect recognition among PD patients,
but these studies did not focus on comorbid depression and
the results are inconsistent [13–16]. Research on depressed
psychiatric patients has reported impairments in facial affect
processing, suggesting that PD patients with depression may
also be at increased risk for these deficits [17–21]. In healthy
adults, the brain regions most typically activated on fMRI
during facial affect processing include the prefrontal cortex
and limbic areas implicated in dPD, providing a rationale for
these tasks as salient in dPD [22].

2. Methods
2.1. Participants. The participants in this study were the same
as those reported in Blonder et al. [2] and consisted of
28 right-handed, nondemented, idiopathic PD patients (10
women, 18 men). Patients were diagnosed by an American
Board of Psychiatry and Neurology-certified neurologist specializing in movement disorders (JTS) using UK Parkinson’s
Disease Brain Bank Clinical Diagnostic Criteria [23]. Patients
with a diagnosis of mild to moderate idiopathic PD (≤3 on the
Hoehn and Yahr scale) were eligible to participate. Patients
were under treatment with levodopa plus carbidopa either
alone or in combination with dopamine agonists. Of the 28
participants, 18 were not depressed (11 men, 7 women) and
10 met DSM-IV diagnostic criteria for a depressive disorder
(7 men, 3 women). Of these, seven had major depressive
disorder; three had minor depression. Three of the ten dPD
patients were taking selective serotonin reuptake inhibitors at
the time of testing, one patient was also receiving a selective
serotonin-norepinephrine reuptake inhibitor, and six were
not receiving antidepressant medication. DPD patients who
were taking antidepressant medication did not discontinue
these medications during the study. Demographic and clinical characteristics of the participants are given in Table 1. All
participants gave written informed consent under a protocol
approved by the University of Kentucky Institutional Review
Board. The participants in this study reflected PD patients
more generally in that the dPD patients both in this sample
and in the population represent slightly more than one-third
of idiopathic PD patients [24] and tend to be younger [25, 26].
Participants attended a screening visit at the University
of Kentucky Medical Center followed by two additional
visits during which they received neuropsychological and
neuroimaging assessments. During one of the two visits
patients took their Parkinson medication as prescribed and
during the other visit they ceased to take anti-Parkinson medication prior to midnight the night before testing. Patients
on dopaminergic medications had their most recent dose
approximately one to two hours prior to testing. The order of
drug-on versus drug-off sessions was counterbalanced across
subjects.
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Table 1: Demographic and clinical data (on PD medication).

Age y, mean (SD)
Education
Men/women
Months since diagnosis
DRS-scaled
NART-R-FSIQ
GDS-15
Hamilton Depression Scale
UPDRS-Motor
UPDRS-Tremor
Schwab-England ADL
Levodopa equivalent daily dose
% on DA agonists

Nondepressed Parkinson’s
patients
[𝑛 = 18; 𝑋 (SD)]

Depressed Parkinson’s
patients
[𝑛 = 10; 𝑋 (SD)]

𝑃 value

68.4 (8.2)
16.0 (3.1)
11/7
55.7 (39.9)
11.0 (2.5)
107.5 (7.8)
1.9 (1.9)
4.6 (3.7)
16.6 (6.3)
1.1 (1.7)
89.2 (11.5)
513.1 (377.7)
61.1

55.2 (7.0)
15.6 (2.3)
7/3
43.6 (44.0)
12.0 (2.5)
99.1 (11.8)
6.2 (3.4)
15.0 (4.6)
15.0 (6.2)
0.9 (1.2)
84.0 (13.5)
525.0 (430.9)
60.0

0.0002∧
NS∧
NS
NS∧
NS∧
0.0321∧
0.0002∧
<0.0001∧
NS∧
NS∧
NS∧
NS∧
NS∗

Note:
DRS: Mattis Dementia Rating Scale.
NART-R-FSIQ: National Adult Reading Test-Revised, Estimated Full-Scale IQ.
GDS-15: Geriatric Depression Scale-15-Item Version.
UPDRS: Unified Parkinson’s Disease Rating Scale.
∧
𝑡-test.
∗ 2
𝜒 test.

2.2. Emotional Face Processing. The functional neuroanatomy of emotional face processing has been well studied.
The brain regions most strongly implicated are the fusiform
gyrus, the superior temporal sulcus, the middle temporal
gyrus, the medial and lateral prefrontal cortex, the anterior
cingulate, and the amygdala. These are areas that have shown
significant activation to neutral and emotionally expressive
faces among healthy volunteers [22, 27–30]. In studies of individuals with PD, Sprengelmeyer et al. [31] found that nevermedicated patients were impaired in the recognition of anger
and disgust compared to medicated patients. Lawrence et al.
[32] found that PD patients withdrawn from dopaminergic
therapy experienced difficulty recognizing anger on the face.
As described above, Tessitore et al. [11] showed a lack of
amygdala activation to angry and fearful facial expressions
in PD patients off dopaminergic medications. None of these
studies focused on Parkinsonian depression nor did they
compare depressed and nondepressed PD patients.
2.3. fMRI Stimuli. Stimuli consisted of grayscale still photographs of human faces from standardized sets published by
Ekman and Friesen [33], Gur et al. [34, 35], and Matsumoto
and Ekman [36]. Faces displayed happy, sad, angry, or neutral
expressions. The choice of these expressions was based
on design considerations and recent literature associating
deficits in the recognition of angry faces with PD [32].
2.4. Presentation. Stimuli were displayed in sequence onto a
translucent screen placed at the rear of the MR scanner using
E-Prime software and an MRI compatible projection system.
Participants viewed this screen from within the bore of the

magnet by means of a mirror placed on the head coil. At the
beginning of a run, pictures from each category were shown.
Data acquired during this “sham” epoch were not used for
analysis. Pictures were subsequently grouped three at a time
into blocks according to stimulus category. Each picture was
shown for 3.7 sec followed by a blank screen lasting 0.5 sec
with picture epochs lasting for 12.6 sec. Picture epochs were
separated by variable-duration periods of rest during which
a fixation point was shown. Fixation periods lasted for 8.4–
12.6 sec with a mean duration of 10.5 sec. Stimulus categories
appeared in random order, and the order of presentation
was counterbalanced within runs as well as across runs
and sessions. Participants were told when viewing a face to
concentrate on what the person is feeling and when viewing
a plus sign to simply concentrate on the image and try not to
think of anything else.
2.5. Image Acquisition and Analysis. fMRI data were collected on a Siemens Magnetom TRIO 3 Tesla imaging
system using the body coil to transmit and an optional 8channel head array coil to receive. A T2 ∗ -weighted gradient
echo EPI sequence was used with acquisition parameters:
TR/TE = 2100/28 msec, FA = 77∘ , matrix = 64 × 64, and
FOV = 224 × 224 mm. Each EPI volume consisted of 38
slices 3.5 mm thick, yielding isotropic voxels. Two runs
were performed, each containing 185 volumes and lasting
about 6.5 minutes. In the same position as the EPI images
we acquired a field map using a double-echo, gradient
echo technique. A 3D MPRAGE sequence (TR/TE/TI =
2100/2.93/1100 msec, FA = 12∘ , FOV = 224 × 256 × 192 mm,
1 × 1 × 1 mm isotropic voxels, sagittal partitions) was used to
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Off dopaminergic drugs

On dopaminergic drugs

Figure 1: Maps thresholded at the same level of statistical significance (𝑃 < 0.001) showing medication-related variations in the response
patterns among depressed and nondepressed PD patients.

collect anatomical images for the localization of functional
responses and for the registration of subjects’ fMRI data sets
across sessions and to stereotactic standard Talairach space
[37].
Image data analysis was performed off-line using Analysis
of Functional Neuroimages (AFNI) software and the Oxford
Center for Functional Magnetic Resonance Imaging of the
Brain (FMRIB) Software Library (FSL). The EPI volumes
comprising the fMRI data were corrected for motion and
slice timing within runs and registered across runs and
across sessions. Geometric distortion correction of the slice
images was done in native space based on the acquired
field map. Voxelwise analysis of the intensity-normalized,
spatially smoothed (3D Gaussian kernel), and concatenated
time series response was subsequently carried out by multiple linear regression, providing simultaneous parameter
estimates for each stimulus category versus a baseline of
fixation comprising 80 EPI volumes. The estimated motion
parameters along with drift terms were included as nuisance
regressors in the baseline model. The box-car shape of the
reference functions for each of the stimulus categories was
convolved with Cohen’s canonical hemodynamic impulse
response function to better reflect the temporal delay and
dynamic nature of the fMRI response. Activation contrasts of
interest measured as fractional signal change were computed
and transformed to standard Talairach coordinate space for
second-level group analyses. Resampling by cubic spline
interpolation in standard space was used, yielding isotropic

2 × 2 × 2 mm voxels. Based upon the spatial resolution of the
raw fMRI data and the amount of spatial smoothing applied
during preprocessing, the activation/deactivation response
measured at each voxel location reflects the average across a
resolution element of size 10 mm on edge. For second-level
group analysis, an exploratory voxelwise random effects analysis of variance was initially carried out with depression as the
between subjects factor (present or absent) and dopaminergic
medication status (on or off) as the within subjects factor. The
dependent response measure was the activation/deactivation
contrast between emotional face stimuli (averaged across all
three emotion categories of happy, angry, and sad) and a
fixation baseline. Note that neutral facial expressions were
not used in this analysis, as comparisons with fixation for
mapping of deactivations within the default-mode network
represent a more appropriate baseline in simulating resting
state. The voxelwise analysis was followed by a region-ofinterest (ROI) analysis using a priori anatomically defined
ROIs and incorporating response measures for each of
the separate emotions as well as controlling for potential
confounds of age and education.

3. Results
Pronounced differences in levels of deactivation of the midline default-mode network as a function of depression and
dopaminergic medication status are readily apparent (see
Figure 1).
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Table 2: VMPFC deactivation responses by group, medication status, and emotion category; values reflect the ROI marginal mean and
standard error.

Depressed PD

Off meds
On meds
Off meds
On meds

The voxelwise analysis of variance (ANOVA) revealed
a significant medication by depression interaction in the
ventromedial prefrontal cortex (VMPFC) with a peak effect at
Talairach location [(𝑥, 𝑦, 𝑧) = (3, 53, 16)]. DPD patients show
greater deactivation on versus off dopaminergic medications
while ndPD patients show the opposite pattern (see Figure 1).
A companion FreeSurfer analysis of the structural MRI
scans did not show any significant differences in medial
prefrontal cortex brain region volume between the groups
of nondepressed and depressed PD patients adjusted for age
and education. The VMPFC location of the peak interaction
effect corresponds to the anterior cingulate cortex region as
defined by the automated anatomical labeling (AAL) atlas
of Tzourio-Mazoyer et al. [38]. A full factorial analysis was
subsequently carried out in SAS v9.3 (SAS Institute Inc.,
Cary, NC) using region-of-interest fMRI response data for
the separate emotions extracted from this anatomical ROI,
referred to in the following as VMPFC. The mean fractional
signal change across all voxels within the ROI was used as the
dependent measure.
An ANOVA for a crossover design was used with
depression as the between subjects factor (present or absent)
and dopaminergic medication status (on or off), emotion
category (angry, happy, or sad), and hemisphere (left or
right) as within subjects factors. Age and education served
as covariates in the analysis, although neither variable was
found to be correlated with the fMRI activation/deactivation
response and therefore would not affect the result. This
analysis revealed a significant three-way interaction between
depression, dopaminergic medication status, and emotion
category (𝐹(2, 48) = 4.76; 𝑃 = 0.013). The three-way
interaction may be driven by a significant interaction between
depression and dopaminergic medication status for happy
faces (𝐹(1, 24) = 6.72; 𝑃 = 0.016). There was no effect of
hemisphere. Table 2 lists the least squares marginal means
averaged across hemispheres for this VMPFC region; the
averages across emotion categories for the depression by
medication design are displayed in Figure 2.
The separate activation/deactivation maps for patient
groups and medication status clearly depict the presence of
this interaction as reflecting varying levels of deactivation
within the default-mode network, a network of brain regions
active when the brain is at rest (see Figure 1). In particular, Figure 2 shows that depressed and nondepressed PD
patients exhibit opposite effects such that dPD patients have
greater deactivation in the VMPFC while on dopaminergic
drugs whereas ndPD patients show greater deactivation off
dopaminergic drugs. The effect of depression itself, manifested as a reduced level of VMPFC deactivation, is clearly

Happy
−0.087 (0.030)
0.010 (0.030)
−0.006 (0.040)
−0.080 (0.040)

Sad
−0.055 (0.030)
−0.085 (0.030)
−0.112 (0.040)
−0.055 (0.040)

Average
−0.082 (0.021)
−0.049 (0.021)
−0.054 (0.027)
−0.093 (0.027)

VMPFC responses (left/right averages)
0
−0.02

Deactivation

Nondepressed PD

Angry
−0.104 (0.030)
−0.071 (0.030)
−0.044 (0.040)
−0.144 (0.040)

−0.04
−0.06
−0.08
−0.1
−0.12

Off
On
Anti-PD medication status
Nondepressed
Depressed

Figure 2: Dopaminergic medication by depression interaction in
the ventromedial prefrontal cortex (VMPFC) in PD patients; data
points depict the average value across emotion categories from the
4th column of Table 2. Error bars represent the standard error of the
mean.

visible in the left-hand activation/deactivation maps for
facial emotion processing tasks acquired off dopaminergic
medication.
An additional interaction effect is present in the ventrolateral prefrontal cortex (VLPFC) of the voxelwise analysis
bilaterally [(𝑥, 𝑦, 𝑧) = (±31, 27, −6)]. The effect is somewhat
more pronounced and spatially extensive in the right hemisphere, although the left-right difference was not statistically
significant. This location is part of the task-positive brain
network activated by emotional faces and corresponds to the
inferior frontal gyrus pars orbitalis region of the AAL atlas
[38]. A separate ANOVA was subsequently carried out using
region-of-interest fMRI response data extracted from this
anatomical ROI, referred to in the following as VLPFC. The
mean fractional signal change across all voxels within the
ROI was again used as the dependent measure. This analysis
revealed a significant depression-by-medication interaction
(𝐹(1, 24) = 7.20; 𝑃 = 0.013) along with a medicationby-emotion interaction (𝐹(2, 48) = 3.44; 𝑃 = 0.040).
Additionally, there is a significant main effect of emotion
category in the VLPFC (𝐹(2, 48) = 4.51; 𝑃 = 0.016)
with less activation to happy faces than to angry and to
sad faces. Figure 3 shows that depressed and nondepressed
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VLPFC responses (left/right averages)
0.12

Deactivation

0.1
0.08
0.06
0.04
0.02
0
Off

On
Anti-PD medication status

Nondepressed
Depressed

Figure 3: Dopaminergic medication by depression interaction in
the ventrolateral prefrontal cortex (VLPFC) in PD patients. Error
bars represent the standard error of the mean.

PD patients exhibit opposite effects such that dPD patients
have greater activation in the VLPFC while off dopaminergic drugs whereas the nondepressed PD patients show
greater activation on dopaminergic drugs. The depressionby-medication interaction may be reflective of a reciprocal
modulation in the prefrontal cortex between the VMPFC and
VLPFC [39–42]. In both nondepressed and dPD patients,
increased activation in VLPFC is associated with decreased
deactivation in VMPFC.
Figure 4 depicts the bivariate nature of the (VMPFC,
VLPFC) activity measures averaged across individual emotions and hemispheres for all ndPD and dPD subjects as
well as off and on their dopaminergic medication. A general
association between increased activation in VLPFC and
decreased deactivation in VMPFC is apparent.

4. Discussion
In sum, we found that dopaminergic medications used to
treat PD have opposite effects in two regions of the prefrontal
cortex depending upon whether or not the patient suffers
from depression. In particular, dPD patients show greater
deactivation in the VMPFC on dopaminergic medications
than they do off. In contrast, ndPD patients show greater
deactivation in this region off these drugs. In the VLPFC, dPD
patients show less activation on dopaminergic medications
versus off, while ndPD patients show the opposite pattern.
The VMPFC is considered a region in the default-mode
network (DMN), that is, a network of brain regions that
remains active during rest periods [43]. Resting activity in the
DMN is reduced when individuals shift attentional resources
from self-referential to task-related processes. DMN activity is negatively correlated with brain systems used for
focused external visual attention. Our results suggest that the
administration of dopaminergic medications to dPD patients

facilitates this shift in attention from self-referential to external foci whereas the administration of dopaminergic medications to nondepressed PD patients impedes this attentional
shift.
Neuropsychiatric research has shown that major depressive disorder and dysthymia are associated with alterations
in the structure and function of the DMN [43–49]. In PET
studies of idiopathic depressed patients, the VMPFC has
been shown to be hyperactive at rest [45, 46]. Similarly, an
event-related fMRI design revealed an elevated tonic level of
VMPFC activity [47] and abnormally increased resting-state
functional connectivity in depression [48]. Hyperactivity
of the VMPFC in depression is typically accompanied by
reduced metabolism and blood flow within dorsal and lateral
prefrontal regions such as the VLPFC [45, 50, 51]. Normal
resting blood flow and metabolism in these PFC regions is
restored upon treatment with antidepressants medications
[52–55].
FMRI studies have found that depressed individuals
show less deactivation of the VMPFC compared to normal controls during externally oriented tasks [44, 47]. For
example, Sheline et al. [44] found that unmedicated patients
with major depression failed to decrease activity in the
DMN, including the VMPFC, when viewing and reappraising
negative pictures. Johnson et al. [56] noted that the lack of
deactivation in the VMPFC during distraction was positively
associated with levels of negative rumination in a group
of largely unmedicated depressed patients. In the present
study, we see a reduced level of VMPFC deactivation in
depressed compared to nondepressed PD patients off their
dopaminergic medications. (Region-of-interest data for a
separate group of 17 age-matched normal control subjects
showed a VMPFC deactivation level of −0.105. Those subjects
were scanned on two separate days without dopaminergic
drugs using the same protocol but are not part of the analysis
for the present study. This normal level of deactivation is
greater than for either subgroup of PD patients.)
In an investigation of antidepressant effect on functional
connectivity in the DMN among dysthymic patients, Posner
et al. [49] found that treatment with the selective serotoninnorepinephrine reuptake inhibitor (SNRI) duloxetine normalized DMN connectivity. Posner et al. [49] noted that while
DMN functional connectivity improved among dysthymic
patients on SNRIs, mood did not. They attributed this
apparent discrepancy to the fact that activity in the DMN
is associated with rumination and the depression scale that
they used did not measure that particular symptom [49, 56].
In the present study, we find greater deactivation in VMPFC
and less activation in VLPFC of dPD patients when performing an emotional face recognition task on dopaminergic
medications versus off, suggesting that dopaminergic drugs
may act similarly to SNRIs in normalizing DMN activity
patterns. Like the findings of Posner et al., medication-related
changes in activity patterns did not translate into improved
mood or affect recognition as these functions declined in
dPD patients on dopaminergic drugs [2]; we also did not
measure rumination. Hypothetically, rumination may have
decreased in dPD patients on dopaminergic drugs in concert
with an increase in VMPFC deactivation and presumed
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0.2

VLPFC activation

increased attention to affective faces. We should point out
that a post hoc analysis of the subgroups of dPD patients on
and off dopaminergic medication shows that the differential
activation patterns seen at the group level are not due to a
large confounding effect of SSRI/SNRI in half of the dPD
patient group. Rather the contributions from the SSRI/SNRI
medicated patients have a diluting effect on the interactions
observed in the VMPFC as well as in the VLPFC.
Our findings may reflect reciprocal modulation in the
prefrontal cortex between the VMPFC and VLPFC. This
is consistent with prior work by Northoff et al. [41] and
Harvey et al. [42]. For example, Northoff et al. [41] found that
both emotional and nonemotional judgments of emotionally
evocative pictures elicited increased activation in VLPFC
and dorsolateral prefrontal cortex (DLPFC) and concurrent
signal decreases in the VMPFC and dorsomedial prefrontal
cortex. Subsequently, Northoff et al. [57] commented on
the see-saw balance between medial and lateral forebrain
regions. They proposed a resting-state hypothesis of major
depressive disorder in which abnormal resting-state activity
leads to reduced rest-stimulus interaction manifested as
reduced task-related deactivation responses in those regions
with high resting-state midcortical activity [41, 58]. In an
fMRI study of working memory in patients with major
depression, Harvey et al. [42] saw increased activation in
the lateral prefrontal cortex and dorsal anterior cingulate
cortex in depressed patients compared to healthy controls.
Performance and reaction times were comparable. These
findings suggest that depressed patients must recruit more
neural resources in order to maintain working memory
performance comparable to normal controls. Furthermore,
Harvey et al. [42] interpreted this as an attempt by depressed
subjects to counter the lack of deactivation in the limbic
PFC by enhancing the activity of the lateral PFC in order
to maintain the same “activity gap” between the two regions
compared to healthy controls. In a review of the literature
on emotion regulation, Phillips et al. [39] proposed a neural
model in which VMPFC activity (among that of other medial
prefrontal regions) is associated with automatic emotion
regulation and VLPFC activity is associated with voluntary
emotion regulation. Sheline et al. [44] noted the failure to
decrease activity in the DMN in depression and suggested
that dysregulation of automatic emotion processing indicates
the fundamental importance of the DMN in depression.
Depressed individuals achieve successful emotion regulation
by recruiting additional lateral prefrontal neural regions
including VLPFC to overcome the dysfunction of VMPFC
[39, 40, 50]. This model is consistent with our data. In fact,
it would appear that the relationship depicted for depressed
and nondepressed groups of PD patients in Figures 2 and
3 holds true across a continuum; thus, our data show a
linear relationship between VMPFC deactivation and VLPFC
activation. The scatter plot in Figure 4 reveals that the slope
of this relationship is similar for depressed and nondepressed
PD patients and is similar to that for a separate group of agematched normal controls scanned under the same protocol
(but not part of this study).
We know of no prior studies that have examined the
effects of dopaminergic medications on neural activity during
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Figure 4: Scatter plots illustrating the relationship between VMPFC
deactivation and VLPFC activation for the emotional face processing task. Observations both on and off dopaminergic medication are
included. Data points for an age-matched group of normal control
subjects are added for comparison. Solid lines depict fits to data
from each group separately. The dashed green lines indicate the 95%
confidence interval for the linear curve fitting data from a separate
group of age-matched normal controls scanned under the same
protocol but not part of this study.

cognitive or affective processing among dPD patients specifically. However, as noted in Introduction, a few studies have
looked at cerebral activation in nondepressed PD patients
or in heterogeneous samples of PD patients on and/or off
dopaminergic medications [8, 10, 11], and some investigators
have focused on the DMN. For example, van Eimeren et
al. [59] used fMRI to examine executive function/shortterm memory in the DMN of PD patients off dopaminergic
medications. They found deactivation of the medial PFC in
both healthy controls and PD patients. However, PD patients
showed significantly less task-associated deactivation in the
posterior cingulate cortex and the precuneus. In addition, the
medial prefrontal cortex and the rostral ventromedial caudate
nucleus were functionally disconnected in PD. The authors
did not exclude patients with dysthymia or minor depression
as indicated by Beck Depression Inventory cut-off scores;
thus the sample was likely heterogeneous making the results
difficult to interpret. Using PET, Argyelan et al. [9] observed
comparable deactivation of the VMPFC during a sequence
learning task in unmedicated ndPD patients and healthy
control participants. When medicated, the ndPD patients
failed to demonstrate learning-related deactivation based on
PET. Our finding that ndPD patients show less deactivation
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of the VMPFC on dopaminergic medication compared to off
is consistent with these results.
Delaveau et al. [60] examined PD patients’ responses to
emotional facial expressions on and off levodopa and found
increased deactivation in the posterior cingulate/precuneus
region of the DMN on medication, suggesting that levodopa
increased patients’ ability to attend to external stimuli. They
did not see any differences in VMPFC deactivation in PD
patients on and off levodopa however. While Delaveau et
al. [60] excluded PD patients with major depression, they
did not exclude patients with mild depression or dysthymia,
providing a possible explanation for the discrepant findings.
Past research suggests that dopaminergic medication
improves or impairs cognitive performance depending on the
nature of the task and on individual variation in the basal
level of dopamine in the underlying corticostriatal circuitry
[10, 61]. Studies indicate that baseline levels of dopamine
influence performance such that low levels accompany poor
performance, which is generally improved by dopamine
analogues or receptor agonists. By contrast, high levels of
baseline dopamine accompany good performance which is
generally impaired by DA receptor analogues and agonists
due to a “levodopa overdose” effect [62, 63]. In our prior
work, ndPD patients did more poorly on cognitive tests off
dopaminergic medication, whereas dPD patients performed
better off drugs [2]. On dopaminergic medication, the pattern
of test scores was reversed with a resulting poorer performance among dPD subjects [2]. In the present fMRI study,
activation of the VLPFC, a region known to be involved also
in cognitive control, exhibits a similar interaction pattern in
its modulation by depression and medication status.
Evidence suggests that genetic polymorphisms in the
catechol O-methyltransferase (COMT) gene influence these
responses. COMT is an enzyme that regulates dopamine
and other catecholamines in various brain regions. The metallele of COMT is associated with higher baseline levels of
dopamine in the prefrontal cortex as well as enhanced working memory, executive function, attention, and reactivity to
negative emotional stimuli on fMRI [64, 65]. The met-allele
is also associated with a higher risk of depression [66, 67] and
may indicate an increased risk of PD as well as variability in
individual response to levodopa therapy [68–71]. Individuals
who are homozygous for the met-allele (high tonic, low
phasic dopamine) have been shown to perform significantly
better on certain cognitive tasks than individuals possessing
the val-allele [72].
Using fMRI with an emotion processing paradigm,
Smolka et al. [64] found that the met-allele was associated with increased activation in VLPFC during passive
viewing of unpleasant stimuli. Upon oral administration
of amphetamine, which is thought to block the reuptake
of dopamine, Mattay et al. [72] observed improvement in
performance on an n-back working memory task among
subjects with the val genotype while performance deteriorated in met subjects who have inherently high basal PFC
dopamine levels. The changes seen in cognitive testing following amphetamine were accompanied by a similar switch
in DLPFC activation when the n-back task was performed
during fMRI data acquisition. These observations provide
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evidence of an inverted-U functional-response curve to
increasing dopamine signaling in the PFC. Interindividual
variation in the effects of dopaminergic drugs may reflect
genetic variations in baseline levels of dopamine and in the
individual’s positioning on this inverted-U shaped curve.
Individuals may therefore exhibit differential sensitivity to
the positive and negative effects of dopaminergic drugs [63].
Argyelan et al. [9] in turn looked at the DMN in PD and
found a reduction in VMPFC deactivation during a sequence
learning task upon administration of levodopa. We see a
similar reduction in the level of VMPFC deactivation in
ndPD patients when performing an emotional face recognition task on dopaminergic medication compared to off.
Depressed PD patients, on the other hand, increase their
level of VMPFC deactivation while on dopamine analogues
and agonists. When Argyelan et al. [9] performed COMT
genotyping of their sample of PD patients, they noticed that
the inverted-U dependence on dopamine level might explain
the changes seen in VMPFC deactivation. In particular,
they observed an interaction between COMT genotype and
levodopa administration status in which levodopa reduced
the magnitude of deactivation in val carriers but enhanced
the deactivation response in met homozygotes. Given that
dopaminergic input to the VMPFC from ventral striatum is
relatively preserved in PD, Argyelan et al. [9] speculated that
this region may be more susceptible to local overdose effects
[62].
In the present study, dPD patients off dopaminergic drugs
exhibited a failure to suppress the default-mode activity
manifested as a reduced level of deactivation in VMPFC
during external stimulation with photographs of emotional
faces. Suppression of the default-mode activity during task
performance was restored by dopaminergic medication. The
inverse effect involving activation of the VLPFC supports
the view of reciprocal limbic-cortical function and negative
mood state [51]. We posit that brain activity in the prefrontal
cortex may follow an inverted-U shape with the effects
of dopaminergic medication dependent upon individual
variation in COMT polymorphisms that influence baseline
dopamine levels (see Figure 5). If true, and in keeping with
the findings of Argyelan et al. [9], we would expect an
association between the met-allele genotype and Parkinson’s
depression to explain increased suppression of the VMPFC
and reduced activation of the VLPFC following administration of dopaminergic medications. Future research will assess
this hypothesis.
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